Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Total Valuation
Seres Therapeutics has a market cap or net worth of $101.23M. The enterprise value is $204.62M.
Market Cap$101.23M
Enterprise Value$204.62M
Share Statistics
Seres Therapeutics has 174.36M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding174.36M
Owened by Insiders0.45%
Owened by Instutions13.81%
Financial Efficiency
Seres Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -113.10%.
Return on Equity (ROE)0.99%
Return on Assets (ROA)0.10%
Return on Invested Capital (ROIC)-113.10%
Return on Capital Employed (ROCE)-123.05%
Revenue Per Employee$0
Profits Per Employee$1,320.398
Employee Count103
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Seres Therapeutics is 949.54. Seres Therapeutics’s PEG ratio is -9.49.
PE Ratio949.54
PS Ratio0.00
PB Ratio9.37
Price to Fair Value9.37
Price to FCF-0.87
Price to Operating Cash Flow-0.87
PEG Ratio-9.49
Income Statement
In the last 12 months, Seres Therapeutics had revenue of $0.00 and earned $136.00K in profits. Earnings per share was -$0.01.
Revenue$0.00
Gross Profit-$2.98M
Operating Income-$126.52M
Pretax Income-$139.67M
Net Income$136.00K
EBITDA-126.10M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -$148.61M and capital expenditures -$380.00K, giving a free cash flow of -$148.99M billion.
Operating Cash Flow-$148.61M
Free Cash Flow-$148.99M
Free Cash Flow per Share-$0.85
Dividends & Yields
Seres Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-115.37%
Earnings Yield0.11%
Stock Price Statistics
Beta0.65
52-Week Price Change-4.84%
50-Day Moving Average0.73
200-Day Moving Average0.86
Relative Strength Index (RSI)41.92
Average Volume (3m)934.99K
Important Dates
Seres Therapeutics upcoming earnings date is May 7, 2025, Before Open.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Seres Therapeutics as a current ratio of 0.94, with Debt / Equity ratio of 6.65
Current Ratio0.94
Quick Ratio0.94
Debt to Market Cap0.71
Net Debt to EBITDA-0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Seres Therapeutics has paid $1.52M in taxes.
Income Tax$1.52M
Effective Tax Rate0.00%
Enterprise Valuation
Seres Therapeutics EV to EBITDA ratio is -1.57, with an EV/FCF ratio of -1.28.
EV to Sales0.00
EV to EBITDA-1.57
EV to Free Cash Flow-1.28
EV to Operating Cash Flow-1.28
Balance Sheet
Seres Therapeutics has $30.79M in cash and marketable securities with $91.64M in debt, giving a net cash position of $60.85M billion.
Cash & Marketable Securities$30.79M
Total Debt$91.64M
Net Cash$60.85M
Net Cash Per Share$0.35
Tangible Book Value Per Share$0.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Seres Therapeutics is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.50
Price Target Upside832.20%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-100.00%
EPS Growth Forecast-7.66%